Advancing

Novel pharmacologic treatments for sleep disorders

Program Indication Preclinical Exploratory Clinical Phase 1 Phase 2 Phase 3
AD109
OSA
Symptomatic Snoring
AD036
OSA
AD275
OSA
AD128 OSA
Undisclosed Programs OSA

learn about our studies

Lead Product Candidate

AD109

Apnimed’s lead product candidate, AD109, targets the neurologic control and facilitates the activation of the upper airway dilator muscles to maintain an open airway during sleep. AD109 is a first-in-class, oral pharmaceutical combination dosed once-daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines a selective norepinephrine reuptake inhibitor (NRI), atomoxetine, with a novel NCE selective antimuscarinic, aroxybutynin. The investigational drug is designed to be safe, effective, and convenient, addressing the key limitations of the current standard of care treatments.

If successful, this pharmacologic approach will substantially change the treatment of patients with disease severity ranging from symptomatic snoring through a substantial proportion of patients with severe OSA.

AD109 has successfully completed early-stage clinical trials and has moved into mid-stage clinical development.

Lead Product Candidate

AD109

AD036

AD036, consisting of the norepinephrine reuptake inhibitor, atomoxetine, combined with the anti-muscarinic oxybutynin, was studied in a large Phase 2 clinical trial that included 140 patients with a broad range of OSA severity from moderate to very severe. AD036 improved multiple objective measures of OSA as well as OSA symptoms, providing proof-of-concept that an oral pharmacologic approach may have clinical benefit in patients with OSA.

Next Generation programs

AD275 is a drug combination that incorporates a carbonic anhydrase inhibitor. AD128 incorporates a novel norepinephrine reuptake inhibitor. Apnimed is also developing other next generation pharmacologic approaches for the treatment of OSA and related disorders.

Next Generation programs